VUITY Drug Patent Profile
✉ Email this page to a colleague
When do Vuity patents expire, and what generic alternatives are available?
Vuity is a drug marketed by Abbvie and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.
This drug has thirty-one patent family members in twenty-three countries.
The generic ingredient in VUITY is pilocarpine hydrochloride. There are twelve drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the pilocarpine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Vuity
A generic version of VUITY was approved as pilocarpine hydrochloride by PADAGIS US on November 16th, 2004.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for VUITY?
- What are the global sales for VUITY?
- What is Average Wholesale Price for VUITY?
Summary for VUITY
| International Patents: | 31 |
| US Patents: | 2 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 75 |
| Patent Applications: | 3,807 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for VUITY |
| What excipients (inactive ingredients) are in VUITY? | VUITY excipients list |
| DailyMed Link: | VUITY at DailyMed |
Pharmacology for VUITY
| Drug Class | Cholinergic Receptor Agonist |
| Mechanism of Action | Cholinergic Agonists Cholinergic Muscarinic Agonists |
Paragraph IV (Patent) Challenges for VUITY
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| VUITY | Ophthalmic Solution | pilocarpine hydrochloride | 1.25% | 214028 | 1 | 2022-12-30 |
US Patents and Regulatory Information for VUITY
VUITY is protected by six US patents and two FDA Regulatory Exclusivities.
Patents protecting VUITY
Presbyopia treatments
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF PRESBYOPIA IN ADULTS BY ADMINISTRATION OF PILOCARPINE HCI FORMULATION TWICE DAILY
Presbyopia treatments
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF PRESBYOPIA IN ADULTS BY ADMINISTRATION OF PILOCARPINE HCI FORMULATION ONCE DAILY
Presbyopia treatments
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: USE OF VUITY FOR THE TREATMENT OF PRESBYOPIA IN ADULTS
Presbyopia treatments
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF PRESBYOPIA IN ADULTS BY ADMINISTRATION OF PILOCARPINE HCI FORMULATION ONCE DAILY
Presbyopia treatments
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF PRESBYOPIA IN ADULTS BY ADMINISTRATION OF PILOCARPINE HCI FORMULATION TWICE DAILY
Presbyopia treatments
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: USE OF VUITY FOR THE TREATMENT OF PRESBYOPIA IN ADULTS
FDA Regulatory Exclusivity protecting VUITY
ADDITION OF SECOND DOSE FOR TREATMENT OF PRESBYOPIA IN ADULTS
Exclusivity Expiration: ⤷ Sign Up
NEW PRODUCT
Exclusivity Expiration: ⤷ Sign Up
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abbvie | VUITY | pilocarpine hydrochloride | SOLUTION;OPHTHALMIC | 214028-001 | Oct 28, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Abbvie | VUITY | pilocarpine hydrochloride | SOLUTION;OPHTHALMIC | 214028-001 | Oct 28, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Abbvie | VUITY | pilocarpine hydrochloride | SOLUTION;OPHTHALMIC | 214028-001 | Oct 28, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for VUITY
See the table below for patents covering VUITY around the world.
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
